Skip to content

Exhaled CO2 sampling during GI Endoscopy Procedures

An Investigation of Exhaled Carbon Dioxide Sampling in Participants Receiving High-Flow Nasal Oxygen (HFNO) During Gastrointestinal (GI) Endoscopic Procedures

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12625000874415
Enrollment
10
Registered
2025-08-12
Start date
2025-10-29
Completion date
2026-11-02
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This single-center, prospective study aims to iteratively assess and improve the reliability of exhaled carbon dioxide sampling in participants receiving high-flow nasal oxygen (HFNO) during gastrointestinal endoscopy procedures. The investigational device is a CO2 sampling device that will sample and measure expired CO2. There is no hypothesis to be tested as this study is an exploratory study.

Interventions

The investigational device is an exhaled CO2 sampling device (CO2-sampler) connected to a capnograph. The CO2-sampler is attached to nasal prongs delivering standard HFNO. The participant will be fitted with the investigational device by the clinical team immediately before the procedure. The investigational device will be on the participant throughout their endoscopic procedure (ranging from 15 mins to 1 hour). Each participant will have the investigational device in situ during their endoscopy

The investigational device is an exhaled CO2 sampling device (CO2-sampler) connected to a capnograph. The CO2-sampler is attached to nasal prongs delivering standard HFNO. The participant will be fitted with the investigational device by the clinical team immediately before the procedure. The investigational device will be on the participant throughout their endoscopic procedure (ranging from 15 mins to 1 hour). Each participant will have the investigational device in situ during their endoscopy procedure only, the investigational device will not be used during any other part of their hospital stay. The anaesthetist will closely observe and monitor the participant throughout their procedure. Adherence to the study will be closely observed by a study team member and notes will be recorded on the study CRF. Different iterations of the investigational device will be included in the study, with each new iteration available approximately 2 months after the use of the first iteration. The first iteration of the sampling device has four small capnography sampling tubes that are attached to HFNO prongs so that there is a sampling tube near each nostril and at each side of the mouth. Subsequent iterations of the sampling device are not predefined and will be modified based on the data collected from the first iteration. All subsequent iterations will include HFNO prongs with one or more capnography samping lines attached positioned near the participants mouth or nose. It is anticipated approximatley five iterations will be included and each will be studied in between 5 and 20 participants.

Sponsors

Fisher & Paykel Healthcare
Lead SponsorCommercial sector/Industry

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Diagnosis
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

- Adult participants (aged 16 years or above) - Undergoing gastrointestinal (GI) endoscopy procedures under anaesthetist-led sedation - Participant's anaesthetist willing to use HFNO for the case - Willing and able to provide informed consent

Exclusion criteria

- Any underlying medical condition that, in the opinion of the participant's clinicians, will be unfavourable for the administration of the oxygen flows specified in the protocol or may impair compliance with the conduct of the investigation

Outcome results

None listed

Source: ANZCTR · Data processed: Jul 23, 2026